Background: Measurement of objective response to chemotherapy using imaging modalities is sometimes
INTRODUCTION
Pancreatic cancer is the fourth-leading cause of cancer-related mortality in the United States and the fifth in Japan. Symptoms of pancreatic cancer include anorexia, weight loss, weakness, fatigue, abdominal pain, and nausea. The nonspecific and mild nature of these initial symptoms often results in delayed diagnosis; consequently, 80% or more of patients initially present with locally advanced or metastatic disease. 1 Therefore, systematic chemotherapy using gemcitabine or other drugs 2 is considered the treatment of choice for patients with this morbidity. Despite the low objective response rate, gemcitabine improves survival and provides a clinical benefit. However, the median survival time is 5.7 months and the one-year survival rate 18%. 3 Recently, a Phase III study 'CONKO-003' provided at first time evidence for the benefit of second-line chemotherapy as compared to best supportive care alone for patients with pancreatic cancer. 4 To facilitate early second-line chemotherapy induction, earlier detection of treatment failure of the first-line chemotherapy is mandatory. Furthermore, earlier discontinuation may limit adverse effects, thereby improving quality of life, and reduce unnecessary costs.
Currently, objective measurement of response to chemotherapy using the Response Evaluation Criteria in Solid Tumors (RECIST) 5 is formally available. However, these criteria are sometimes difficult to apply to pancreatic cancer, which comprises inflammatory cells and fibrotic tissue as well as malignant cells. 6 Under a computed tomography (CT) scan, it is difficult to discriminate the tumor component from others. 7 In addition, the evaluation of progressive disease for non-measureable lesions such as ascites, pleural effusion, and pericardiac effusion, is subjective and equivocal.
Tumor markers (TMs) have often been identified as surrogate markers. For example, a decrease in CA19-9 during chemotherapy has been reported to be useful for predicting the outcome of patients with pancreatic cancer in some retrospective studies. [8] [9] [10] [11] [12] [13] [14] [15] We expected that use of such a TM may enable us to detect early treatment failure of pancreatic cancer during chemotherapy, which has not been established.
The aim of this study is to verify whether monitoring of serum TMs, such as carcinoembryonic antigen (CEA), CA19-9, DUPAN-2, and SPan-1, can facilitate earlier detection of treatment failure during chemotherapy for pancreatic cancer than evaluation with the RECIST criteria.
PATIENTS AND METHODS

Patients
The patients analyzed in this study were enrolled in the randomized controlled trial UMIN ID 974, entitled "A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity". 16 Therefore, all patients had unresectable, histologically or cytologically proven, locally advanced or metastatic pancreatic adenocarcinoma. Other eligibility criteria included no prior therapy, Karnofsky Performance Status ≥50%, age between 20 and 80 years, life expectancy of more than 2 months, and adequate organ function defined as white blood cell count ≥3000/mm 3 , neutrophils ≥1500/mm 3 , platelets ≥100000/mm 3 , hemoglobin ≥9.0 g/dl, total bilirubin ≤2.0 mg/dl (or ≤3.0 mg/dl if biliary drainage was present), AST and ALT ≤2 times the upper limit of normal (ULN) (or ≤5 times the ULN if liver metastasis was present), and creatinine ≤ the 9 ULN. The number of patients enrolled in this original study was 90.
All patients understood the nature of the study, and written informed consent was obtained from all of them. The local ethics committee approved this treatment protocol. In addition, all patients agreed with the analysis of their clinical data including this study.
Chemotherapy and Assessment of Efficancy and Toxicity
Patients were randomly assigned to either the 4-week or 3-week schedule of gemcitabine monotherapy. . Once a dose reduction was required, reescalation of dose was not allowed. A delay in the cycle of up to 2 weeks during one course was allowed when grade 2-4 hematological toxicity was recorded on day 1 of each cycle. When recovery from treatment-related toxicity required more than 2 weeks, the gemcitabine treatment was stopped.
A CT scan was performed at baseline and every 4 weeks during chemotherapy until objective findings of disease progression were noted. Tumor response (i.e. maximum response during treatment) was assessed according to the RECIST criteria every 4 weeks. In addition, clinically severe symptoms related with progressing cancer, such as aggravated general condition, uncontrollable pain and GI obstruction, were also regarded as progressive disease (PD), namely, clinical PD. Treatment decisions were based on these radiographic and clinical grounds, and not on serum TM concentrations. Treatment was continued for at least 2 months and until progression of disease, occurrence of unacceptable toxicity, or patient refusal.
Patients who had unacceptable toxicity or refused therapy were excluded from this study.
Tumor response by RECIST criteria
Tumor response was categorized as complete response, partial response, stable disease, or PD by RECIST criteria. 5 All patients with evidence of a complete response or partial response or stable disease on at least one occasion were considered to have unconfirmed response. Confirmed responses were those documented with a follow-up CT scan obtained 4 weeks or longer after the scan that documented the initial response. Time to tumor progression (TTP) was defined as the time from initial therapy to the first objective documentation of tumor progression or clinically severe symptoms such as those described above.
Serum tumor markers measurement
Serum CEA, CA19-9, DUPAN-2, and SPan-1 were measured at baseline (on day 1 of first cycle of gemcitabine monotherapy) and every 4 weeks thereafter, on the same day of CT scan assessment. The CEA and CA19-9 were measured using an electrochemiluminescence immunoassay (ECLIA), DUPAN-2 using an enzyme immunoassay (EIA), and SPan-1 using an immunoradiometric assay (IRMA) at all institutions. In addition, the ULN of CEA was 5 ng/ml, that of CA19-9 was 37 U/ml, that of SPan-1 was 30 U/ml, and that of DUPAN-1 was 150 U/ml. Baseline and follow-up measurements for any given patient were performed at the same laboratory and by the same method.
Evaluation
Positive rates for each TM before initial chemotherapy were calculated in patients who were enrolled in this original study. TMs having values higher than the upper limit of normal were considered as indicators which should be investigated. After selecting some TMs with higher pretreatment positive rates than the others, we made the following analysis. 
Statistical analysis
Continuous data are presented as medians and ranges. Continuous variables were compared with
Mann-Whitney U test. Frequency distribution was compared with Fisher's exact test or the χ 2 test.
Pearson's correlation coefficient was used to analyze the relationship between TTP and TM-TTP. Paired t test was used to compare between TTP and TM-TTP. Detection of treatment failure using the relationship between TTP and TM-TTP was evaluated by sign test. Survival analysis was assessed by the Kaplan-Meier method, and the survivals of Group A and Group B were compared using the log-rank test.
All statistical analyses were performed with JMP 8.0.1 software (SAS Institute). A P-value <0.05 was considered statistically significant.
RESULTS;
Positive rate for each TM
The positive rate for each TM before induction of chemotherapy was 50% (45/90) for CEA, 83% (75/90) for CA19-9, 73% (59/81) for DUPAN-2, and 90% (73/81) for SPan-1, respectively. Nine of 90 patients were excluded from the SPan-1 and DUPAN-2 analyses as these markers had not been measured in these patients. From our results, since CA19-9 and SPan-1 had high positivity rates, we selected these two TMs for the subsequent analysis.
Seventy-three of 90 patients (81.1%) received gemcitabine until progression of disease and 17 patients (18.9%) discontinued gemcitabine chemotherapy due to unacceptable toxicity or refusal of treatment.
TM fluctuation ratio one month after initial chemotherapy by tumor responses in CA19-9 and
SPan-1
The median TM fluctuation ratio of CA19-9 one month after initial chemotherapy induction was 27% (interquartile range [IQR]: 0% to 112%) in PD patients, -12% (IQR: -41% to 25%) in stable disease and -68% (IQR: -73% to -22%) in partial response. Similarly, the median TM fluctuation ratio of SPan-1 one month after initial chemotherapy induction was 11% (IQR: -10% to 57%) in PD patients, -24% (IQR:
-43% to 6%) in stable disease and -48% (IQR: -72% to -10%) in partial response.
Evaluation of disease progression from the CA19-9 fluctuation ratio
The positive rate for CA19-9 before induction of chemotherapy among the patients who received gemcitabine until progression of disease was 83.6% (60/73). However, 56 of 60 patients (93.3%) were eligible for the analysis of CA19-9, because inadequate data accumulation regarding CA19-9 was noted in 4 patients ( Table 1- 
Evaluation of disease progression from the changes of a combination of CA19-9 and SPan-1
Forty-nine of 73 patients (67%) who had both positive CA19-9 and SPan-1 before treatment were eligible for the analysis of combination of CA19-9 and SPan-1. We could make an earlier confirmation of treatment failure in 72% of these patients using TM-PD criteria of both CA19-9 and SPan-1 (Table 3) .
Monitoring the combination of CA19-9 and SPan-1 could significantly facilitate earlier confirmation of PD compared with CA19-9 alone (P = 0.004).
Discussion;
This report is based on prospectively collected data from a cohort studied in a randomized controlled trial. 16 Our data show that monitoring of serum CA19-9 and SPan-1 facilitates the earlier confirmation of the treatment failure by approximately one month in patients with pancreatic cancer during gemcitabine monotherapy. Furthermore, the combination of these two TMs ensures an increase in sensitivity. Certainly, one-month earlier confirmation may be short. However, their median TTP and median survival time were only 3.9 months and 8.2 months, respectively. Therefore, measuring the TTP-TM has a considerable clinical impact regarding the change of chemotherapy.
CA19-9 is a tumor-associated antigen (first described by Koprowski et al. 17 ) defined by a monoclonal antibody (1116 NS 19-9). Using a cutoff point of 37 U/ml as the ULN, the overall sensitivity of the assay in detecting pancreatic cancer was previously found to be approximately 80% with a specificity of 90%. 18 Furthermore, CA19-9 can change in association with tumor shrinkage or disease progression 19 , and therefore changes in serum CA19-9 concentration during treatment often serve as a parameter for efficacy in the setting of a clinical trial. 20 Regarding the usefulness of CA19-9 in patients receiving chemotherapy for advanced pancreatic cancer, a decrease in CA19-9 concentration has been proposed as a surrogate marker for survival in several retrospective studies 9, 10, 11, 13, 15, 20, 21 , and pretreatment CA19-9 values have been an independent predictor for survival in some other studies. 12, 21, 22 However, in former studies, different definitions of CA19-9 response were used (between 20% and 50% decrease from pretreatment CA19-9). In this study, we made a definition of TM-PD for earlier confirmation of PD. As mentioned in the Patients and Methods section, we defined the criteria of TM-PD from the analysis of TM fluctuation ratio in Group A, which was applicable to the analysis of early confirmation of treatment failure in Group B. As a result, we found that the TM fluctuation ratio could serve an earlier detection marker of disease progression than RECIST criteria.
Formerly, Rocha, Lima et al found a strong correlation between CA19-9 progression and TTP with CA19-9 progression preceding radiographic progression in most of their patients. 23, 24 However, in their studies, CA19-9 was measured every 3 weeks and imaging studies were performed every 6 weeks. In our study, both the imaging study and the measurement of TMs were performed every 4 weeks. This is the strength of our study because our data was feasible for detailed analysis. Therefore, our study supports a more precise correlation between TM-TTP and TTP.
Ko et al reported that a rising/nondeclining CA19-9 appeared to be a clear indicator of early progressive disease and to correlate with very poor clinical outcomes. 10 In our study, there were marked differences in However, CA19-9 is a sialylated Lewis a (Le) a blood group antigen and individuals with Lewis-negative phenotype (lacking the Lewis antigen glycosyltranferase), who comprise approximately 5% of the population, are unable to synthesize CA19-9. 25 Kawa et al reported that DUPAN-2 was the precursor of CA19-9. Furthermore, they described that SPan-1 had an advantage over CA19-9 in the diagnosis of patients with Lewis-negative phenotype. In addition, the two markers had almost the same sensitivity for this malignancy. 26 In our study, although DUPAN-2 was not used as a marker for assessment of early confirmation of disease progression, SPan-1 was found to be as useful a marker as CA19-9 for the evaluation of disease control. In fact, SPan-1 could detect treatment failure earlier than RECIST criteria in 59% of the cases (Table 2-B) . Moreover, in the case of the patients whose CA19-9 and SPan-1 values were both more than the baseline (81%: 66/81 in our study), we could make earlier confirmation of treatment failure by using TM-PD criteria of both CA19-9 and SPan-1 (72%, 35/49; Table 3 ). Accordingly, it is suggested that the monitoring of TMs during chemotherapy using our method can facilitate the change of treatment at an earlier point in the disease course.
There are some limitations to our study. The number of patients was small and the two regimens using gemcitabine were included. However, we could demonstrate that there was statistically significant correlation between TM-TTP and TTP regarding CA19-9 and SPan-1 (r = 0.798, P<0.001; r = 0.465, P = 0.006; respectively). As for the regimen, although cases with both 4-week and 3-week gemcitabine-monotherapy schedules were included, the regimen was randomly allocated. Furthermore, in this trial, the 3-week regimen demonstrated the same efficacy and less toxicity compared with the 4-week regimen. 16 Future larger studies are required to establish the role of CA19-9 and SPan-1 monitoring as a biomarker to confirm disease progression earlier in patients with pancreatic cancer treated with gemcitabine.
In conclusion, monitoring of serum CA19-9 and/or SPan-1 is helpful for earlier confirmation of treatment failure in the treatment of patients with pancreatic cancer during gemcitabine monotherapy. The only chance to improve the prognosis of patients with pancreas cancer is changing the chemotherapeutic regimens when the first such regimen fails. Despite the existence of few promising second-line therapies, it is suggested that our findings will assist physicians in deciding on changes of regimen earlier in the progression of disease, when imaging findings are still equivocal. Comparison between median TM-TTP and median TTP † P = 0.738 * P value was calculated by sign test.: P = 0.001 † P value was calculated by median test. Comparison between median TM-TTP and median TTP † P = 0.727 * P value was calculated by sign test.: P = 0.049 † P value was calculated by median test. Comparison of time to progression of tumor marker (TM-TTP) using a combination of CA19-9 and SPan-1 with TM-TTP using CA19-9 CA19-9 → CA19-9 ＋SPan-1; n, (%) P values were calculated by sign test.: * P = 0.152, † P = 0.004 ‡ P values were calculated by median test.
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